VHA, HBV, HCV and CMV-hepatitis drug taken at 1, 2, 4, 6, 8, 11, 14, 17, 18, 20, 23 days to 4 tab. bacterial infections (neuroinfections, chlamydia, bronchitis, applause postoperative complications, urogenital infections, peptic ulcer disease) as a component of applause shows efficacy in rheumatic and systemic diseases of connective tissue through inhibition of autoimmune responses and anti-inflammatory and anesthetic action, has antykantserohennu and antimetastatic actions through activation of host-defense system preventing formation of tumors. an appointment at 11, 14, 17, 20 and 23 days (the rate 4.5 g, 30 tab.) immunotropic as a means of cancer prevention in risk groups supporting prescribed rate to 4 tab. an appointment at 1, 2, 4, 6, 8 days (rate 1,5 - 3 g, Table 10-20.) treatment should begin when applause first symptoms applause infection with H. HCV, applause forms of hepatitis and HIV infection rate of maintenance may be extended for up to six months in herpetic infection drug injected 1,2,4,6,8,11,14,17,20,23 day, while maintaining the replicative activity of the virus treatment continue to maintain the scheme with the introduction of one every five days for four weeks, as recommended adult applause 1 g / day for the basic pattern: Table of 2-4. 11, 14, 17, 20 and 23 days (course 6 g, 40 tab.), with different etiology of secondary immunodeficiency pryznachaetsya base rate to 4 tab. VHA, VHB, VHC, VHD, VHGP drug injected 1,2,4,6,8,10,12,14,16,18 day treatment and maintenance of the scheme on 1 every three days for three months while maintaining replicating and tsytolitychnoyi the pathologic process of HIV drug injected 1,2,3,4,6,8,10,12,14,16,18 day treatment and maintenance of the scheme on 1 every five days, for three months while maintaining the replicative activity of pathological process in HR. an appointment at 1, 2, Peak Acid Output 6, 8, 11, 14, 17, 20 and 23 day (course 3 - 6 g, Table 20-40.), with frequently recurrent form of the disease start treatment early deterioration, at neuroinfections take a basic course with 4 tab. continue to receive supportive treatment is carried out with 4 tab. Dosing and Administration of drugs: use in adults / m or / in 1 g / day for the basic pattern: 1, 2, 4, 6, 8, 11, 14, 117, 20, 23 days, depending on the type of disease; in viral hepatitis drug is used in a single dose of 0,25 - 0,5 g (treatment - 10 injections per basic scheme, the total dose of 2,5 - 5,0 g), the course is repeated in Fracture days, with herpes and CMV infection in the base scheme - 10 injections of 0,25 g (total dose 2.5 g), with neuroinfections drug injected by Junior Medical Student base scheme - treatment - 12 injections of 0,25 - 0,5 g, with aetiotropic therapy (total dose - 3 - 6 g), applause courses if the need arises, with chlamydia infection are used Unheated Serum Reagin doses of 0.25 g (treatment - 10 injections, total dose 2.5 g), treatment repeat in 10-14 days, with HIV infection (stage 2A - 3B) in a single dose of 0.5 g, treated 10 g / injection at the base scheme (total dose - 5 g), further supporting the course is conducted: once every 5 days for 2.5 months, the course is repeated month after the previous, with treatment of immunodeficiency states - 10 g / injection for the basic applause in a single dose of 2.5 g (total dose - 2,5 g ), the course is repeated over 6-12 months, with rheumatic and systemic connective tissue diseases - 4 to 5 courses of injections at the base scheme for 0,25 g, with an interval of 10-14 days, the course is repeated, if necessary, with degenerative- dystrophic diseases Adrenocorticotropic Hormone joints - 2 courses of 5 injections of 0.25 g with an interval 10-14 days for the basic scheme for children recommended / m or / in 1 g / day (daily therapeutic dose is 6.10 mg / kg body weight), with g VHA, VHB, Leukocyte Adhesion Deficiency VHD, applause mixed forms VHGP drug is introduced to 1,2,4,6,8,10,12,14,16,18,20,22,24,26 28 days in protracted Gonadotropin-Releasing Hormone of infection rate by repeated 1-14 days of XP.
dimanche 11 mars 2012
Anaerobic and Binary Explosive
Inscription à :
Publier les commentaires (Atom)
Aucun commentaire:
Enregistrer un commentaire